Eton Pharmaceuticals, Inc. (ETON): debt financing — Eton Pharmaceuticals amends credit facility: rate reduced, interest-only extended to Nov 2026

Eton Pharmaceuticals, Inc.

Interest rate reduced to SOFR plus 6.55% (from 6.75%); SOFR floor lowered from 5.0% to 2.75%.
Interest-only period extended to November 2026; optional principal payment in May 2026 or deferral.
No fees paid to SWK for amendment; maturity unchanged at December 2027.
Amendment conditions included consummation of Runway/SWK merger; representations and warranties reaffirmed.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Eton Pharmaceuticals, Inc. amended credit facility with SWK Funding LLC at SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0% maturing December 2027.

Instrument: credit facility
Counterparty: SWK Funding LLC
Rate: SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%
Maturity: December 2027
Event: amendment

Exact text from the filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Eton Pharmaceuticals, Inc. amended SWK Credit Agreement with SWK Funding LLC (effective 2026-04-09).

Action: amendment
Agreement: credit facility
Counterparty: SWK Funding LLC
Effective: 2026-04-09

Exact text from the filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”).

View on SEC.gov

Browse all debt financings →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-012381

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.